

K072526

OCT 5 2007

**510(k) Summary**

**Micrus Endovascular Corporation  
Micrus® Courier Enzo™ Microcatheter 0.0190"**

This 510(k) summary for the Micrus® Courier Enzo™ Microcatheter 0.0190" is submitted in accordance with the requirements of 21 C.F.R. § 807.92.

**GENERAL INFORMATION**

**Manufacturer:** Micrus Endovascular Corporation  
821 Fox Lane  
San Jose, California 95131  
Phone: (408) 433-1400  
Est. Registration No. 2954740

**Contact Person:** R. Michael Crompton  
Vice President, Regulatory / Clinical Affairs  
& Quality

**Date Prepared:** September 6, 2007

**DEVICE DESCRIPTION**

**Classification:** Class II

**Trade Name:** Micrus® Courier Enzo™ Microcatheter 0.0190"

**Generic/Common Name:** Diagnostic intravascular catheter (21 CFR § 870.1200)

**PREDICATE DEVICE**

Micrus® Courier Enzo™ Microcatheter 0.0170" (reference: K070456)

**INTENDED USE**

The Micrus Courier microcatheters are intended to assist in the delivery of diagnostic agents, such as contrast media, and therapeutic agents, such as occlusion coils, into peripheral, coronary, and neuro vasculature.

K072526

## DEVICE DESCRIPTION

The Micrus® Courier Enzo™ Microcatheter 0.0190" is a diagnostic intravascular catheter with an in-vivo shapeable tip which deflects under operator control at an angle of  $\pm 90^\circ$  from the neutral position. The Micrus® Courier Enzo™ Microcatheter 0.0190" is designed with a feature which allows the clinician to adjust the catheter tip shape *in-vivo* by turning a knob. No shaping tool is required. This design feature allows the clinician to adjust the catheter tip shape to accommodate variations in patient anatomy without having to remove the catheter from the patient's body in order to re-shape it.

The accessories for the Micrus Courier Enzo Microcatheter 0.0190", which are not supplied as part of the sales unit, are identical to those for the Micrus Courier Pre-Shaped Microcatheters and include:

- Guiding catheter (generally, 5-7F)
- Guidewire compatible with the microcatheter
- Rotating Hemostatic Valves (RHV); two (2) required
- 3-way stopcock
- 1-way valve
- Femoral sheath
- Continuous Saline Flush Set-ups with Pressure Bags, one as a flush for the guiding catheter and the other as a flush for the microcatheter

## SUBSTANTIAL EQUIVALENCE

The Micrus® Courier Enzo™ Microcatheter 0.0190" is substantially equivalent to the predicate device identified previously. The Micrus® Courier Enzo™ Microcatheter 0.0190" is substantially equivalent to the predicate device with regard to intended use, shape of distal tip angle, materials, design, and function.

Verification testing conducted on the Micrus® Courier Enzo™ Microcatheter 0.0190" demonstrates the device is substantially equivalent to the predicate device and does not raise new questions regarding safety and effectiveness with respect to diagnostic intravascular catheters when used in accordance with its Instructions for Use.

## CONCLUSION

As described in this 510(k) Summary, Micrus Endovascular Corporation considers the Micrus® Courier Enzo™ Microcatheter 0.0190" substantially equivalent to the Micrus® Courier Enzo™ Microcatheter 0.0170" based on a comparison of intended uses and the results of *in-vitro* tests.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Micrus Endovascular Corporation  
c/o Mr. R. Michael Crompton  
Vice President, Regulatory/Clinical Affairs & Quality  
821 Fox Lane  
San Jose, CA 95131

OCT 5 2007

Re: K072526

Trade/Device Name: Micrus® Courier Enzo™ Microcatheter 0.0190”  
Regulation Number: 21 CFR 870.1200  
Regulation Name: Diagnostic intravascular catheter  
Regulatory Class: Class II  
Product Code: DQO  
Dated: September 6, 2007  
Received: September 7, 2007

Dear Mr. Crompton:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set


Page 2 – Mr. Crompton

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometrics' (OSB) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Bram D. Zuckerman, M.D.  
Director  
Division of Cardiovascular Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

K072526

### Statement of Indications for Use

510(k) Number (if known): K \_\_\_\_\_

Device Name: Micrus® Courier Enzo™ Microcatheter – 0.0190"

Indications for Use: The Micrus Courier microcatheters are intended to assist in the delivery of diagnostic agents, such as contrast media, and therapeutic agents, such as occlusion coils, into peripheral, coronary, and neuro vasculature.

Prescription Use  X   
(Per 21 C.F.R. 801 Subpart D)


AND/OR

Over-the-Counter Use \_\_\_\_\_  
(21 C.F.R. 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER  
PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
\_\_\_\_\_  
(Division Sign-Off)  
Division of Cardiovascular Devices  
510(k) Number  K072526

Page 1 of 1